Papillon-Cavanagh et al. analysed the impact of STK11 and KEAP1 mutations in tumour samples from non-squamous NSCLC on the benefit of anti-PD-1/PDL-1 therapies, EGFR tyrosine kinase inhibitors, anti-vascular endothelial growth factor (VEGF), platinum-based combination chemotherapy or single-agent chemotherapy [26]. The gene discussed is STK11; the disease is neoplasm.